XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Revenues - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]      
Total revenues $ 27,281 $ 27,305 $ 24,689
U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 18,884 19,267 18,217
Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 4,469 4,874 4,135
Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 3,928 3,164 2,337
Product sales      
Disaggregation of Revenue [Line Items]      
Total revenues 26,982 27,008 24,355
Product sales | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 18,716 19,176 18,141
Product sales | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 4,342 4,678 3,894
Product sales | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 3,924 3,154 2,320
Total HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 17,194 16,315 16,938
Total HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 13,820 12,828 13,651
Total HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 2,219 2,366 2,287
Total HIV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 1,155 1,121 1,000
Biktarvy      
Disaggregation of Revenue [Line Items]      
Total revenues 10,390 8,624 7,259
Biktarvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 8,510 7,049 6,095
Biktarvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 1,103 969 735
Biktarvy | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 777 606 429
Complera/Eviplera      
Disaggregation of Revenue [Line Items]      
Total revenues 200 258 269
Complera/Eviplera | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 74 102 89
Complera/Eviplera | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 113 142 159
Complera/Eviplera | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 13 14 21
Descovy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,872 1,700 1,861
Descovy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,631 1,397 1,526
Descovy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 118 164 197
Descovy | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 123 139 138
Genvoya      
Disaggregation of Revenue [Line Items]      
Total revenues 2,404 2,879 3,338
Genvoya | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,983 2,267 2,605
Genvoya | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 284 391 490
Genvoya | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 136 221 243
Odefsey      
Disaggregation of Revenue [Line Items]      
Total revenues 1,469 1,568 1,672
Odefsey | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,058 1,076 1,172
Odefsey | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 364 440 450
Odefsey | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 47 52 50
Stribild      
Disaggregation of Revenue [Line Items]      
Total revenues 127 189 196
Stribild | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 88 132 125
Stribild | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 29 43 54
Stribild | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 10 14 17
Truvada      
Disaggregation of Revenue [Line Items]      
Total revenues 147 371 1,448
Truvada | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 113 314 1,376
Truvada | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 15 22 27
Truvada | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 18 35 45
Revenue share - Symtuza      
Disaggregation of Revenue [Line Items]      
Total revenues 530 531 488
Revenue share - Symtuza | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 348 355 331
Revenue share - Symtuza | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 168 165 149
Revenue share - Symtuza | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 14 11 8
Other HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 57 195 407
Other HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 15 136 332
Other HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 24 30 26
Other HIV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 17 29 49
Veklury      
Disaggregation of Revenue [Line Items]      
Total revenues 3,905 5,565 2,811
Veklury | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,575 3,640 2,026
Veklury | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 702 1,095 607
Veklury | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 1,628 830 178
Total HCV      
Disaggregation of Revenue [Line Items]      
Total revenues 1,810 1,881 2,064
Total HCV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,005 1,018 1,088
Total HCV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 413 421 414
Total HCV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 392 442 562
Ledipasvir/Sofosbuvir      
Disaggregation of Revenue [Line Items]      
Total revenues 115 212 272
Ledipasvir/Sofosbuvir | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 46 84 92
Ledipasvir/Sofosbuvir | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 17 31 29
Ledipasvir/Sofosbuvir | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 51 97 151
Sofosbuvir/Velpatasvir      
Disaggregation of Revenue [Line Items]      
Total revenues 1,530 1,462 1,599
Sofosbuvir/Velpatasvir | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 844 815 864
Sofosbuvir/Velpatasvir | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 355 316 337
Sofosbuvir/Velpatasvir | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 331 331 398
Other HCV      
Disaggregation of Revenue [Line Items]      
Total revenues 166 207 193
Other HCV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 115 119 132
Other HCV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 40 74 48
Other HCV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 10 14 13
Total HBV/HDV      
Disaggregation of Revenue [Line Items]      
Total revenues 988 969 860
Total HBV/HDV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 435 397 380
Total HBV/HDV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 112 104 71
Total HBV/HDV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 441 468 409
Vemlidy      
Disaggregation of Revenue [Line Items]      
Total revenues 842 814 657
Vemlidy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 429 384 356
Vemlidy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 35 34 29
Vemlidy | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 379 396 272
Viread      
Disaggregation of Revenue [Line Items]      
Total revenues 91 111 185
Viread | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 6 11 14
Viread | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 23 28 34
Viread | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 62 72 137
Other HB/HDV      
Disaggregation of Revenue [Line Items]      
Total revenues 55 44 18
Other HB/HDV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 0 2 10
Other HB/HDV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 55 42 8
Other HB/HDV | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 0 0 0
Total cell therapy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,459 871 607
Total cell therapy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 968 542 396
Total cell therapy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 430 293 201
Total cell therapy | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 60 36 10
Tecartus      
Disaggregation of Revenue [Line Items]      
Total revenues 299 176 44
Tecartus | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 221 136 34
Tecartus | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 75 40 10
Tecartus | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 3 0 0
Yescarta      
Disaggregation of Revenue [Line Items]      
Total revenues 1,160 695 563
Yescarta | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 747 406 362
Yescarta | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 355 253 191
Yescarta | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 57 36 10
Trodelvy      
Disaggregation of Revenue [Line Items]      
Total revenues 680 380 49
Trodelvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 525 370 49
Trodelvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 143 10 0
Trodelvy | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 12 0 0
Total Other      
Disaggregation of Revenue [Line Items]      
Total revenues 946 1,027 1,026
Total Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 388 381 551
Total Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 323 389 314
Total Other | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 235 257 161
AmBisome      
Disaggregation of Revenue [Line Items]      
Total revenues 497 540 436
AmBisome | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 57 39 61
AmBisome | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 258 274 230
AmBisome | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 182 227 145
Letairis      
Disaggregation of Revenue [Line Items]      
Total revenues 196 206 314
Letairis | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 196 206 314
Letairis | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 0 0 0
Letairis | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 0 0 0
Other      
Disaggregation of Revenue [Line Items]      
Total revenues 253 281 276
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 135 136 176
Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 65 115 84
Other | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues 53 30 16
Royalty, contract and other revenues      
Disaggregation of Revenue [Line Items]      
Total revenues 299 297 334
Royalty, contract and other revenues | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 168 91 76
Royalty, contract and other revenues | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 127 196 241
Royalty, contract and other revenues | Other International      
Disaggregation of Revenue [Line Items]      
Total revenues $ 4 $ 10 $ 17